Regeneron Pharma gains on strong Q2 and earnings beat

Regeneron Pharmaceuticals (REGN) Q2 results:

Revenues: $1,952M (+23.7%); Eylea sales in U.S.: $1,113.7M (-4.0%); Dupixent global net sales: $945M (+70%); Libtayo global sales: $80M (+96%); Praluent: $86.6M (+18%); Kevzara: $68.3M (+17%).

Net Income: $897M; EPS: $7.61; non-GAAP Net Income: $854M (+23.8%); non-GAAP EPS: $7.16 (+18.9%).

CF Ops (3 months): $943.4M (401.0%).

https://seekingalpha.com/news/3600709-regeneron-pharma-gains-on-strong-q2-and-earnings-beat